• Virus-Mimicking Nanoparticles Enable Targeted Extrahepatic m

  2026-06-30

  The referenced study introduces a self-assembling enveloped virus-mimicking particle (EVMP) system that enables precise, efficient mRNA delivery to non-liver tissues such as the lung and spleen. By overcoming the hepatic tropism, immunogenicity, and scalability barriers of conventional platforms, this innovation holds significant promise for gene editing and therapeutic mRNA applications targeting extrahepatic organs.

• AI-10-49 in AML: Mechanistic Dissection and Translational Im

  2026-06-29

  Discover how AI-10-49, a potent CBFβ-SMMHC inhibitor, enables precise dissection of leukemogenic mechanisms in acute myeloid leukemia research. This article uniquely bridges molecular pharmacology with practical experimental strategy for advanced leukemia model systems.

• D-N-Acetylgalactosamine: Protocol Parameters for Brain Glyco

  2026-06-29

  D-N-Acetylgalactosamine supports reproducible analysis of glycoprotein structure and glycosylation pathways in neurological research, especially brain heteropolysaccharide studies. It is unsuitable for workflows requiring ethanol solubility or long-term storage of solutions.

• M344 HDAC Inhibitor: Precision Epigenetic Control in Neurobl

  2026-06-28

  Explore how M344, a potent histone deacetylase inhibitor, enables advanced, mechanism-driven interrogation of neuroblastoma and cancer epigenetics. This article unpacks new preclinical insights and practical workflow guidance for achieving rigorous cell differentiation and apoptosis assay results.

• A40926: Dalbavancin Precursor for High-Precision Antibacteri

  2026-06-27

  A40926 stands out as a rigorously characterized dalbavancin precursor, empowering researchers with superior in vitro and in vivo potency for Gram-positive and multidrug-resistant pathogen studies. Discover how to optimize experimental workflows, troubleshoot common pitfalls, and leverage biosynthetic innovations for advanced antibacterial research.

• Tivozanib (AV-951): Redefining Anti-Angiogenic Cancer Resear

  2026-06-26

  This article delivers a strategic, evidence-driven analysis of Tivozanib (AV-951) as a potent and selective VEGFR tyrosine kinase inhibitor, weaving mechanistic insights with actionable guidance for translational oncology researchers. It uniquely integrates recent advances in in vitro drug response quantification, highlights differentiators versus other pan-VEGFR inhibitors, and offers a visionary blueprint for next-generation anti-angiogenic research workflows.

• Ruxolitinib Phosphate Disrupts DRP1-Mediated Fission in Anap

  2026-06-26

  This study demonstrates that Ruxolitinib phosphate (INCB018424) induces apoptosis and pyroptosis in anaplastic thyroid carcinoma (ATC) by inhibiting DRP1-mediated mitochondrial fission via JAK1/2-STAT3 signaling suppression. These mechanistic findings highlight a novel therapeutic strategy for targeting aggressive thyroid malignancies.

• Enhanced Production of A40926 via Engineered N. gerenzanensi

  2026-06-25

  This study demonstrates a significant improvement in the fermentation yield of A40926, a key dalbavancin precursor, using polygenic engineering and medium optimization in Nonomuraea gerenzanensis. The findings advance scalable antibiotic production and enable more robust in vitro antibacterial assay workflows for Gram-positive infection research.

• Naloxone Hydrochloride: Optimizing Opioid Receptor Antagonis

  2026-06-25

  Naloxone hydrochloride offers unparalleled precision as an opioid receptor antagonist, enabling advanced workflows in neural stem cell modulation and opioid withdrawal studies. This article details actionable protocols, troubleshooting insights, and unique applications that distinguish APExBIO’s Naloxone (hydrochloride) for translational and behavioral neuroscience research.

• Z-LEHD-FMK: Irreversible Caspase-9 Inhibitor for Precision A

  2026-06-24

  Z-LEHD-FMK empowers researchers to dissect mitochondria-mediated apoptosis with unprecedented selectivity and reproducibility. Discover how this irreversible caspase-9 inhibitor optimizes experimental workflows, enables advanced cancer and neuroprotection models, and provides robust troubleshooting strategies for reliable assay results.

• Caspase-3 Fluorometric Assay Kit: Precision in Apoptosis Ass

  2026-06-23

  The Caspase-3 Fluorometric Assay Kit empowers researchers with rapid, DEVD-dependent caspase activity measurement, essential for dissecting apoptosis and cell death pathways in cancer and neurodegenerative disease models. This guide details experimental workflows, advanced troubleshooting, and insights from recent studies on resveratrol-induced apoptosis in renal carcinoma cells.

• MG-132 (Z-LLL-al): Unlocking Proteasome Inhibition for Apopt

  2026-06-23

  MG-132 (Z-LLL-al) is a gold-standard, cell-permeable proteasome inhibitor enabling high-fidelity apoptosis assays, cell cycle studies, and oxidative stress modeling. This article distills workflow protocols, troubleshooting insights, and translational strategies leveraging MG-132’s unique biochemical selectivity, with direct relevance to cancer and hypoxic injury research.

• Omeprazole (A2845): H+,K+-ATPase Inhibitor for Gastric Acid

  2026-06-22

  Omeprazole (A2845) addresses the need for a high-purity, research-grade H+,K+-ATPase inhibitor in studies of gastric acid secretion and antiulcer activity. It is suitable for in vitro and ex vivo workflows but must not be used for diagnostic, clinical, or therapeutic applications. Researchers should follow technical best practices for compound handling to ensure reproducible results.

• CRISPR Disruption of scaRNA1 Alters U2 snRNA Modification an

  2026-06-22

  This study demonstrates that targeted CRISPR-Cas9 disruption of scaRNA1 in HEK293T cells reduces pseudouridylation at U2 snRNA position U89, leading to widespread transcriptome changes. The findings illuminate mechanistic links between noncoding RNA-guided modifications and alternative splicing, providing insight into developmental and disease processes.

• Cholesterol as a Keystone in Translational mRNA-LNP Research

  2026-06-21

  Explore how cholesterol, the principal sterol, anchors next-generation lipid nanoparticle design for mRNA therapeutics, with mechanistic depth and actionable protocol guidance for translational researchers. This article bridges advanced membrane biology with strategic perspectives on localized bladder cancer therapy, highlighting the unique value of APExBIO’s high-purity cholesterol. Evidence-backed recommendations and expert commentary set this resource apart from standard product pages.

452 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page